Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GOSS 
Gossamer Bio Inc (GOSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: GOSS (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.61
1 Year Target Price $7.61
| 4 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.38% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 309.13M USD | Price to earnings Ratio - | 1Y Target Price 7.61 |
Price to earnings Ratio - | 1Y Target Price 7.61 | ||
Volume (30-day avg) 9 | Beta 1.85 | 52 Weeks Range 0.66 - 1.55 | Updated Date 07/12/2025 |
52 Weeks Range 0.66 - 1.55 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -41.13% | Operating Margin (TTM) -372.23% |
Management Effectiveness
Return on Assets (TTM) -12.68% | Return on Equity (TTM) -500.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 253983910 | Price to Sales(TTM) 2.48 |
Enterprise Value 253983910 | Price to Sales(TTM) 2.48 | ||
Enterprise Value to Revenue 2.04 | Enterprise Value to EBITDA -0.39 | Shares Outstanding 227302000 | Shares Floating 183746504 |
Shares Outstanding 227302000 | Shares Floating 183746504 | ||
Percent Insiders 3.51 | Percent Institutions 75.98 |
Upturn AI SWOT
Gossamer Bio Inc
Company Overview
History and Background
Gossamer Bio, Inc. is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Founded in 2015, Gossamer Bio went public in 2019. The company focuses on developing new therapeutic approaches to address high unmet medical needs.
Core Business Areas
- Clinical Development: Focuses on advancing a pipeline of product candidates through clinical trials.
- Drug Discovery: Involves identifying and developing novel therapeutic candidates.
- Research and Development: Conducting pre-clinical and clinical studies to support drug development.
Leadership and Structure
The leadership team includes key executives in research and development, clinical operations, and finance. The organizational structure is typical of a biopharmaceutical company, with departments dedicated to research, clinical trials, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- GB002 (seralutinib): A dry powder formulation of a novel inhaled DPI formulation of seralutinib. Gossamer Bio sold GB002 (seralutinib) and the entire seralutinib program to Viatris. Competitors were United Therapeutics (UTHR) and Liquidia Corporation (LQDA).
- Others: Gossamer Bio also has a few other early-stage development programs for various other indications.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. It is also highly competitive, with numerous companies vying to develop and market new therapies.
Positioning
Gossamer Bio has been focused on specific niches within the immunology, inflammation and oncology spaces. Their competitive advantage relies on novel therapeutic candidates and efficient clinical development strategies.
Total Addressable Market (TAM)
The total addressable market is determined by the indications they are pursuing. This can be in the billions of dollars annually, especially in areas like pulmonary hypertension and oncology. Gossamer Bio aims to capture a share of this market through successful drug development and commercialization.
Upturn SWOT Analysis
Strengths
- Experienced management team
- Novel drug candidates
- Focus on high unmet medical needs
Weaknesses
- Dependence on clinical trial outcomes
- High cash burn rate
- Reliance on capital markets for funding
Opportunities
- Successful clinical trial results
- Partnerships and collaborations
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- UTHR
- LQDA
- LLY
- JNJ
- MRK
- BMY
Competitive Landscape
Gossamer Bio faces competition from both large pharmaceutical companies and smaller biotechnology firms. Their competitive advantage depends on developing novel therapies that address unmet medical needs.
Major Acquisitions
None
- Year: 0
- Acquisition Price (USD millions): 0
- Strategic Rationale: No acquistions have occurred.
Growth Trajectory and Initiatives
Historical Growth: Gossamer Bio's growth has been focused on advancing its pipeline of drug candidates. They are not yet profitable, and are focused on drug development.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals. Analyst estimates may vary based on the perceived probability of success of their pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for drug candidates and pursuing strategic partnerships.
Summary
Gossamer Bio is a biopharmaceutical company that sold off their leading drug to Viatris. This has shored up the balance sheet. Further growth requires further clinical advances or strategic partnerships. The company faces challenges common to development stage biotechs, including regulatory hurdles and reliance on R&D outcomes. Investors must monitor their clinical trial progress and competitive landscape closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- News Articles
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available information. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gossamer Bio Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2019-02-08 | Co-Founder, CEO, President & Chairman Mr. Faheem Hasnain | ||
Sector Healthcare | Industry Biotechnology | Full time employees 144 | Website https://www.gossamerbio.com |
Full time employees 144 | Website https://www.gossamerbio.com | ||
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.